The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer
Abstract
PURPOSE OF REVIEW: This review highlights selective androgen receptor modulators (SARMs) as emerging agents in late-stage clinical development for the prevention and treatment of muscle wasting associated with cancer. RECENT FINDINGS: Muscle wasting, including a loss of skeletal muscle, is a cancer-related symptom that begins early in the progression of cancer and affects a patient's quality of life, ability to tolerate chemotherapy, and survival. SARMs increase muscle mass and improve physical function in healthy and diseased individuals, and potentially may provide a new therapy for muscle wasting and cancer cachexia. SARMs modulate the same anabolic pathways targeted with classical steroidal androgens, but within the dose range in which expected effects on muscle mass and function are seen androgenic side-effects on prostate, skin, and hair have not been observed. Unlike testosterone, SARMs are orally active, nonaromatizable, nonvirilizing, and tissue-selective anabolic agents. SUMMARY: Recent clinical efficacy data for LGD-4033, MK-0773, MK-3984, and enobosarm (GTx-024, ostarine, and S-22) are reviewed. Enobosarm, a nonsteroidal SARM, is the most well characterized clinically, and has consistently demonstrated increases in lean body mass and better physical function across several populations along with a lower hazard ratio for survival in cancer patients. Completed in May 2013, results for the Phase III clinical trials entitled Prevention and treatment Of muscle Wasting in patiEnts with Cancer1 (POWER1) and POWER2 evaluating enobosarm for the prevention and treatment of muscle wasting in patients with nonsmall cell lung cancer will be available soon, and will potentially establish a SARM, enobosarm, as the first drug for the prevention and treatment of muscle wasting in cancer patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Steiner introduced Enobosarm, Veru's investigational selective androgen receptor modulator (SARM) [30, 31].”
From Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions (2025) · cites this paper as [31]
Citations
Cites
Dobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Self-citationPapanicolaou, D. A., Ather, S. N., Zhu, H., Zhou, Y., Lutkiewicz, J., Scott, B. B., & Chandler, J. (2013) · The Journal of nutrition, health and aging · doi:10.1007/s12603-013-0335-x · Cited by 196
Basaria, S. S., Collins, L. F., Dillon, E. L., Orwoll, K., Storer, T. W., Miciek, R., Ulloor, J., Zhang, A., Eder, R. V., Zientek, H., et al. (2010) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls078 · Cited by 169
Alanine Aminotransferase Regulation by Androgens in Non-hepatic Tissues
Coss, C. C., Bauler, M. N., Narayanan, R., Miller, D. D., & Dalton, J. T. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0649-5 · Cited by 20
Self-citationAn overview on selective androgen receptor modulators: Focus on enobosarm
Jones, A. J., Coss, C. C., Steiner, M. S., & Dalton, J. T. (2013) · Drugs of the Future · doi:10.1358/dof.2013.038.05.1970866 · Cited by 9
Self-citation
Research works printed but not linked: 1
- Marcantonio, 2010, A 12-week pharmacokinetic and pharmacodynamic study of two selective androgen receptor Modulators (SARMs) in postmenopausal subjects (Abstract P2-2)., Endocr Rev, 31, S871
Cited by
Cancer cachexia: understanding the molecular basis
Argilés, J. M., Busquets, S., Stemmler, B., & López-Soriano, F. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3829 · Cited by 1,517
“(AgRP(83-132)) prevents cachexia-related symptoms”
Muscle metabolism and atrophy: let’s talk about sex
Rosa-Caldwell, M. E., & Greene, N. P. (2019) · Biology of Sex Differences · doi:10.1186/s13293-019-0257-3 · Cited by 202
“Hypogonadism also commonly accompanies cancer cachexia [117, 118], and recent works have begun to evaluate the sufficiency of drugs with androgen-like binding and testosterone itself as pharmacological agents for the treatment of cancer cachexia in men [123, 124].”
BackgroundAndrogen receptor antagonists for prostate cancer therapy
Helsen, C., den Broeck, T. V., Voet, A. R. D., Preković, S., Poppel, H. V., Joniau, S., & Claessens, F. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0545 · Cited by 172
“2005b) and has also served as a template for the development of several selective AR modulators (SARMs), such as Ostarine and LGD-4033 (Dalton et al. 2013).”
Anabolic agents: recent strategies for their detection and protection from inadvertent doping
Geyer, H., Schänzer, W., & Thevis, M. (2014) · British Journal of Sports Medicine · doi:10.1136/bjsports-2014-093526 · Cited by 132
Selective androgen receptor modulators: the future of androgen therapy?
Christiansen, A. R., Lipshultz, L. I., Hotaling, J. M., & Pastuszak, A. W. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2019.11.02 · Cited by 155
“This allows for targeted therapeutic benefits with the absence of adverse off-target effects, which is currently a significant limitation of TTh. SARMs are well tolerated, and their oral bioavailability provides a substantial advantage over other methods of androgen therapy.”
BackgroundInfluential
Metadata
- Authors
- Dalton, J. T., Taylor, R. P., Mohler, M. L., & Steiner, M. S.
- Affiliations
- GTx (United States) (US)
- Corresponding author
- Dalton, James T.
- Venue
- Current Opinion in Supportive & Palliative Care
- Published
- 2013-12
- Volume
- 7
- Issue
- 4
- Pages
- 345-351
- ISSN
- 1751-4258 (ISSN-L)
- OpenAlex
- W2006607907
- Cited by
- 91
- References
- 5
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 2 · 2023: 6 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 4 · 2018: 10 · 2017: 10 · 2016: 7 · 2015: 9 · 2014: 9
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Supportive and Palliative Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- selective androgen receptor modulators, cancer cachexia, enobosarm, ostarine, skeletal muscle mass, physical function, non-small cell lung cancer, androgenic side effects
- MeSH terms
- Androgen Antagonists, Cachexia, Humans, Muscular Atrophy, Neoplasms, Receptors, Androgen, Muscle, Skeletal, Anabolic Agents, Androgen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. https://app.cochat.ai/papers/10.1097/spc.0000000000000015
- The paper
- Dalton, J. T., Taylor, R. P., Mohler, M. L., & Steiner, M. S. (2013). Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Current Opinion in Supportive & Palliative Care. https://doi.org/10.1097/spc.0000000000000015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.